7 results on '"Gunthart M"'
Search Results
2. Genetically Engineered Mesenchymal Stem Cells Confer Beneficial Effects on Both Co-transplanted Human Embryonic Stem Cell Derived Cardiomyocytes as well as the Recipient Heart
- Author
-
Kearns-Jonker, M., Dai, W.D., Gunthart, M., Girish, N., Pera, M., Mummery, C., and Kloner, R.A.
- Subjects
Myocardial infarction ,Stem cell therapy ,Angiography ,Gene expression ,Angiogenesis - Published
- 2010
3. IGVH GENES ENCODING XENOANTIBODIES TO GALTKO XENOANTIGENS IN RHESUS MONKEYS ARE RESTRICTED
- Author
-
Kearns-Jonker, M, primary, Harnden, I, additional, Kiernan, K, additional, Gunthart, M, additional, Meisner, J, additional, and Gregory, C, additional
- Published
- 2008
- Full Text
- View/download PDF
4. Xenoantibody response to porcine islet cell transplantation using GTKO, CD55, CD59, and fucosyltransferase multiple transgenic donors.
- Author
-
Chen Y, Stewart JM, Gunthart M, Hawthorne WJ, Salvaris EJ, O'Connell PJ, Nottle MB, d'Apice AJ, Cowan PJ, and Kearns-Jonker M
- Subjects
- Amino Acid Sequence, Animals, Base Sequence, Biomarkers metabolism, CD55 Antigens genetics, CD55 Antigens metabolism, CD59 Antigens genetics, CD59 Antigens metabolism, Fucosyltransferases genetics, Fucosyltransferases metabolism, Galactosyltransferases genetics, Galactosyltransferases metabolism, Gene Knockout Techniques, Genetic Markers, Graft Rejection prevention & control, Immunoglobulin M genetics, Molecular Sequence Data, Papio, Animals, Genetically Modified, Antibodies, Heterophile metabolism, Graft Rejection immunology, Immunoglobulin M metabolism, Islets of Langerhans Transplantation methods, Swine genetics, Transplantation, Heterologous methods
- Abstract
Background: Promising developments in porcine islet xenotransplantation could resolve the donor pancreas shortage for patients with type 1 diabetes. Using α1,3-galactosyltransferase gene knockout (GTKO) donor pigs with multiple transgenes should extend xenoislet survival via reducing complement activation, thrombus formation, and the requirement for exogenous immune suppression. Studying the xenoantibody response to GTKO/hCD55/hCD59/hHT islets in the pig-to-baboon model, and comparing it with previously analyzed responses, would allow the development of inhibitory reagents capable of targeting conserved idiotypic regions., Methods: We generated IgM heavy and light chain gene libraries from 10 untreated baboons and three baboons at 28 days following transplantation of GTKO/hCD55/hCD59/hHT pig neonatal islet cell clusters with immunosuppression. Flow cytometry was used to confirm the induction of a xenoantibody response. IgM germline gene usage was compared pre- and post-transplant. Homology modeling was used to compare the structure of xenoantibodies elicited after transplantation of GTKO/hCD55/hCD59/hHT pig islets with those induced by GTKO and wild-type pig endothelial cells without further genetic modification., Results: IgM xenoantibodies that bind to GTKO pig cells and wild-type pig cells were induced after transplantation. These anti-non-Gal antibodies were encoded by the IGHV3-66*02 (Δ28%) and IGKV1-12*02 (Δ25%) alleles, for the immunoglobulin heavy and light chains, respectively. IGHV3-66 is 86.7% similar to IGHV3-21 which was elicited by rhesus monkeys in response to GTKO endothelial cells. Heavy chain genes most similar to IGHV3-66 were found to utilize the IGHJ4 gene in 85% of V-D regions analyzed. However, unlike the wild-type response, a consensus complementary determining region 3 was not identified., Conclusions: Additional genetic modifications in transgenic GTKO pigs do not substantially modify the structure of the restricted group of anti-non-Gal xenoantibodies that mediate induced xenoantibody responses with or without immunosuppression. The use of this information to develop new therapeutic agents to target this restricted response will likely be beneficial for long-term islet cell survival and for developing targeted immunosuppressive regimens with less toxicity., (© 2014 John Wiley & Sons A/S.)
- Published
- 2014
- Full Text
- View/download PDF
5. Genetically Engineered Mesenchymal Stem Cells Influence Gene Expression in Donor Cardiomyocytes and the Recipient Heart.
- Author
-
Kearns-Jonker M, Dai W, Gunthart M, Fuentes T, Yeh HY, Gerczuk P, Pera M, Mummery C, and Kloner RA
- Abstract
AIMS: Human embryonic stem cell-derived cardiomyocytes (hESC-CMs) or mesenchymal stem cells (MSCs) facilitate post-infarct recovery, but the potential benefit of combination therapy using MSCs and hESC-CMs has not been examined. Our objective was to define the gene expression changes in donor and host-derived cells that are induced in vivo after co-transplantation of cardiomyocytes with and without mesenchymal stem cells expressing the prosurvival gene heme oxygenase 1. METHODS AND RESULTS: Human MSCs were engineered to over-express heme oxygenase-1 (HO-1) following lentiviral vector-mediated transduction. Athymic nude rats were subjected to myocardial infarction and received hESC-CMs alone, hESC-CMs plus human MSCs, hESC-CMs plus MSCs overexpressing HO-1, or saline. Real time PCR identified gene expression changes. Cardiac function was assessed by angiography. Co-transplantation of unmodified MSCs plus hESC-CMs elevated CXCR4, HGF, and IGF expression over levels induced by injection of hESC-derived cardiomyocytes alone. In animals co-transplanted with MSC over-expressing HO-1, the expression of these genes was further elevated. Gene expression levels of VEGF, TGF-β, CCL2, SMAD7, STAT3 and cardiomyocyte transcription factors were highest in the HO-1 MSC plus hESC-CM group at 30 days. Human CD31+, CD34+, isl-1+, NXK2.5 and c-kit+ transcripts were elevated. Rodent genes encoding NKX2.5, troponin T and CD31 were elevated and cell cycle genes were induced. Ejection fraction improved by six to seven percent. CONCLUSIONS: Co-administration of HO-1 MSCs plus hESC-CMs increased expression of pro-survival and angiogenesis-promoting genes in human cells and transcripts of cardiac and endothelial cell markers in rodent cells, consistent with activation of tissue repair in both transplanted hESC-CMs and the host heart.
- Published
- 2012
- Full Text
- View/download PDF
6. Identification of an anti-idiotypic antibody that defines a B-cell subset(s) producing xenoantibodies in primates.
- Author
-
Fischer-Lougheed J, Gregory C, White Z, Shulkin I, Gunthart M, and Kearns-Jonker M
- Subjects
- Amino Acid Sequence, Animals, Base Sequence, CD11b Antigen analysis, Disaccharides immunology, Gene Library, Genes, Immunoglobulin, Immunoglobulin Heavy Chains genetics, Immunoglobulin Variable Region genetics, Macaca mulatta, Molecular Sequence Data, Sus scrofa, Transplantation, Heterologous, Antibodies, Anti-Idiotypic immunology, Antibodies, Heterophile biosynthesis, B-Lymphocyte Subsets immunology
- Abstract
Synthetic anti-idiotypic antibodies represent a potentially valuable tool for the isolation and characterization of B cells that produce xenoantibodies. An anti-idiotypic antibody that binds to a subset of B cells producing antibodies encoded by the variable-region heavy chain 3 (V(H)3) germline genes DP35 [immunoglobulin variable-region heavy chain 3-11 (IGHV3-11)], DP-53 and DP-54 plus a small number of V(H)4 gene-encoded antibodies in humans has recently been identified. These germline progenitors also encode xenoantibodies in humans. We tested whether the small, clearly defined group of B cells identified with this anti-idiotypic antibody produce xenoantibodies in non-human primates mounting active immune responses to porcine xenografts. Peripheral blood B cells were sorted by flow cytometry on the basis of phenotype, and cDNA libraries were prepared from each of these sorted groups of cells. Immunoglobulin V(H) gene libraries were prepared from the sorted cells, and the V(H) genes expressed in each of the sorted groups were identified by nucleic acid sequencing. Our results indicate that xenoantibody-producing peripheral blood B cells, defined on the basis of binding to fluorescein isothiocyanate (FITC)-conjugated galactose alpha(1,3) galactose-bovine serum albumin (Gal-BSA) and the anti-idiotypic antibody 2G10, used the IGHV3-11 germline gene to encode xenoantibodies and were phenotypically CD11b+ (Mac-1+) and CD5-. This novel reagent may be used in numerous applications including definition of xenoantibody-producing B-cell subsets in humans and non-human primates and immunosuppression by depletion of B cells producing anti-Gal xenoantibodies.
- Published
- 2008
- Full Text
- View/download PDF
7. Gene therapy for the induction of chimerism and transplant tolerance.
- Author
-
Gunthart M and Kearns-Jonker M
- Subjects
- Animals, Humans, Genetic Therapy, Transplantation Chimera, Transplantation Tolerance
- Abstract
Technical advances in transplant surgery and the development of powerful and effective immunosuppressive drugs have contributed to the success of organ transplantation as a medical treatment for patients with end-stage diseases. Associated with this procedure, however, is a dependence on life-long immunosuppressive drugs, which are required to prevent graft rejection. These agents render the patient susceptible to infections, tumors and various side affects. The ability to achieve tolerance to organ grafts would free transplant patients from lifelong dependency on pharmacological agents with harmful side effects. Several laboratories have shown that tolerance can be achieved by the induction of mixed cell chimerism and/or by molecular chimerism achieved by gene transfer techniques prior to graft placement. Molecular chimerism, induced by transplantation of autologous bone marrow expressing either allo- or xenoantigens has the potential to induce tolerance without the development of graft vs. host disease. The application of gene transfer techniques to induce chimerism has been shown to reshape the immune repertoire by mechanisms that include clonal deletion, the induction of central tolerance or generation of regulatory T cells that would eliminate the need for immunosuppressive drugs. Optimization of this methodology for clinical use could therefore revolutionize the field of transplantation. This review summarizes the recent studies which have compared the efficacy of different vectors, conditioning regimens, and transduction conditions leading to new and improved techniques for the application of gene therapy to induce chimerism and transplant tolerance to both allografts and xenografts.
- Published
- 2007
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.